BoffitoM, WatersL, CahnP, et al.: Perspectives on the barrier to resistance for dolutegravir + lamivudine, a 2-drug antiretroviral therapy for HIV-1 infection. AIDS Res Hum Retroviruses, 2019; 36:13–18.
2.
TaiwoBO, ZhengL, StefanescuA, et al.: ACTG A5353: A pilot study of dolutegravir plus lamivudine for initial treatment of human immunodeficiency virus-1 (HIV-1)-infected participants with HIV-1 RNA <500000 Copies/mL. Clin Infect Dis, 2018; 66:1689–1697.
3.
GibsonRM, MeyerAM, WinnerD, et al.: Sensitive deep sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism. Antimicrob Agents Chemother, 2014; 58:2167–2185.
4.
CahnP, MaderoJS, ArribasJR, et al.: Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): Week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet, 2019; 393:143–155.
